Effect of anakinra (soluble interleukin - 1 receptor antagonist) as combination therapy: second UK combination therapy in early rheumatoid arthritis.

Trial Profile

Effect of anakinra (soluble interleukin - 1 receptor antagonist) as combination therapy: second UK combination therapy in early rheumatoid arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2016

At a glance

  • Drugs Anakinra (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CARDERA-2
  • Most Recent Events

    • 02 Feb 2016 Results published in the Clinical and Experimental Rheumatology
    • 01 Jan 2010 New source identified and integrated (ISRCTN: Current Controlled Trials).
    • 13 May 2009 UKCRN reports end date as 31 Dec 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top